Albright et al. BMC Cancer 2012, 12:138 http://www.biomedcentral.com/1471-2407/12/138 Page 5 of 7 Table 3 Genealogical Index of Familiality for cancers with at least 200 cases with genealogy data, ranked by empirical significance for overall excess relatedness (and ranked by case GIF where the overall empirical significance values are equivalent) Cancer N Case Mean Control Case Mean Control SD Control SD Control Empirical p Empirical p GIF GIF dGIF dGIF GIF dGIF GIF dGIF Chronic Lymphocytic 978 7.90 4.76 5.10 4.14 0.26 0.20 < 0.0001 < 0.0001 Leukemia Small Intestine 387 7.49 4.67 4.56 4.12 0.53 0.38 < 0.0001 0.137 Lip 1077 7.26 4.83 4.89 4.14 0.25 0.20 < 0.0001 0.0001 Thyroid 1865 6.38 4.49 4.48 4.07 0.13 0.11 < 0.0001 0.0006 Testis 691 5.97 4.37 4.18 4.01 0.26 0.20 < 0.0001 0.1943 Multiple Myeloma 1268 5.90 4.76 4.59 4.14 0.21 0.17 < 0.0001 0.0067 Prostate 18069 5.57 4.76 4.44 4.15 0.03 0.03 < 0.0001 < 0.0001 Melanoma 4463 5.56 4.57 4.53 4.11 0.08 0.07 < 0.0001 < 0.0001 Colon 6285 5.49 4.78 4.26 4.13 0.07 0.06 < 0.0001 0.0233 Lung/Bronchus 5063 5.42 4.75 4.27 4.14 0.08 0.07 < 0.0001 0.046 Rectum 2472 5.38 4.73 4.34 4.13 0.13 0.11 < 0.0001 0.032 Kidney 1791 5.35 4.65 4.36 4.12 0.15 0.13 < 0.0001 0.035 Ovary 1941 5.32 4.68 4.27 4.11 0.14 0.12 < 0.0001 0.1042 Non Hodgkin Lymphoma 3267 5.26 4.65 4.44 4.12 0.10 0.08 < 0.0001 0.0002 Breast 12523 5.10 4.70 4.16 4.12 0.04 0.04 < 0.0001 0.2009 Stomach 1490 5.66 4.86 4.32 4.16 0.19 0.16 0.0001 0.1553 Pancreas 1893 5.45 4.77 4.32 4.13 0.16 0.13 0.0001 0.0757 Bladder 2455 5.29 4.84 4.15 4.14 0.13 0.11 0.0008 0.4479 Hodgkin Lymphoma 752 5.25 4.44 3.88 4.03 0.26 0.20 0.0018 0.7628 Endometrial 3155 5.04 4.72 4.03 4.12 0.11 0.09 0.002 0.8261 Cervix 922 5.35 4.68 4.20 4.12 0.26 0.20 0.007 0.3315 Larynx 427 6.06 4.76 4.41 4.14 0.52 0.38 0.0121 0.2366 Brain 1488 4.83 4.45 4.03 4.03 0.16 0.13 0.0124 0.5067 Anus 396 6.33 4.98 4.81 4.17 0.62 0.43 0.0226 0.079 Genital Female 365 6.01 4.75 4.32 4.12 0.60 0.43 0.0266 0.3117 Salivary 338 5.95 4.68 4.52 4.13 0.61 0.44 0.0286 0.1808 Liver/Hepatic 449 5.50 4.63 4.32 4.10 0.47 0.34 0.0418 0.253 Pharynx 315 5.82 4.64 3.30 4.10 0.65 0.46 0.0447 0.9682 Acute Myelogenous 920 5.01 4.62 3.84 4.09 0.25 0.19 0.0651 0.8933 Leukemia Tongue 347 5.57 4.65 3.49 4.13 0.58 0.42 0.0686 0.9418 Acute Lymphocytic 409 4.58 4.14 3.98 3.83 0.38 0.27 0.1284 0.2822 Leukemia Gallbladder 306 5.49 4.90 4.15 4.15 0.77 0.53 0.2106 0.4799 Esophagus 520 4.83 4.71 3.90 4.15 0.42 0.31 0.3814 0.7854 Chronic Myelogenous 343 4.59 4.69 4.16 4.10 0.61 0.44 0.5345 0.4319 Leukemia Oropharynx 261 4.48 4.68 3.37 4.13 0.77 0.54 0.5686 0.9274 Bone 294 3.66 4.34 3.66 3.97 0.56 0.40 0.9014 0.7829 testing, all but 8 of the cancers considered show signifi- cant overall excess clustering of cases. The 8 sites not showing a significant excess even when considered inde- pendently all have small samples sizes (261 ≤ n ≤ 920) and many have recognized environmental risk factors (e. g., esophageal cancer and smoking). Some of the cancers with a non-significant overall p-value had borderline sig- nificant excess (e.g. AML and tongue cancer) and some cancer sites had a much higher case GIF than matched control GIF (e.g. gallbladder cases = 5.49 and controls =